Kuwait: Kuwaiti fitness officials have revealed that the Japanese drug Avigan, also known as Favipiravir, is definitely running on the remedy of COVID-19 patients, local media reported.
The drug was administered to 20 patients with COVID-19 over a 10-day period. One source told Al Qabas that the drug has been shown to be effective, especially in the elderly.
The source is under pressure that Avigan is used in accordance with Japanese guidelines, World Health Organization (WHO) recommendations and Kuwaiti regulations.
According to the effects of the patients who took the drug, the maximum of them came back negative at five days, 10 days for those who did not use the drug.
The source added that recovery rates are likely to increase as fitness officials begin prescribing the drug to more PATIENTS with COVID-19, especially those with shortness of breath.
Although the drug has been effective, the Ministry of Health continues to monitor the progression of medicines in vaccines produced in countries.
In June, the Ministry of Health recently won Avigan’s first shipment, following clinical trials, according to a member of the ministry’s auxiliary drug and medical equipment branch, Dr. Abdullah Al Bader.
Developed through Toyama Chemical Co of Japan, a subsidiary of Fujifilm Holdings, Avigan is a flu medicine for manufacturing and sale in Japan in 2014.
Although the drug gained floor in April, it was recently discouraged because clinical studies were disappointing and regulatory review slowed, Reuters reported.
Last month, Fujita University of Health announced that the Avigan clinical trial, conducted between March and May on 89 patients across Japan, was inconclusive.
Currently, at least 25 Avigan clinical trials are ongoing worldwide. The Philippines began a nine-month clinical trial on August 17 at 4 hospitals on manila Island, the country’s capital.
Dear reader,
This segment is about life in the United Arab Emirates and data you cannot live without.
Sign up to read and complete gulfnews. com